MedTrace Logo

Phenotyping Seroconversion Following Vaccination Against COVID-19 in Patients on Haemodialysis Study

NCT04815850 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 115

Last updated 2024-09-26

Study results available
· View outcomes & findings →

Summary

Patients on haemodialysis are at higher risk of getting a severe form of COVID-19 if they become infected. Vaccinations are soon to arrive and offer great hope of controlling the current pandemic. It is likely that patients on haemodialysis will be amongst the first people to be offered vaccination against COVID-19 when they become available. While any vaccines offered to these patients will be safe to receive, the effectiveness of the vaccines at giving immunity to being infected with COVID-19 are not known as they have not been explicitly tested in patients on haemodialysis. This study will involve having 3 blood tests to test for an antibody response following vaccination for COVID-19. The first will be 1 month after the first vaccination dose to look at the initial antibody response and the second and third will be 1 month and 6 months after the second vaccination dose.

Conditions

Sponsors & Collaborators

  • Leicester Hospitals Charity

    collaborator OTHER

  • Francis Crick Institute

    collaborator OTHER

  • University of Leicester

    lead OTHER

Principal Investigators

  • Matthew PM Graham-Brown · University of Leicester

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2022-02-15
Completion
2022-12-05

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04815850 on ClinicalTrials.gov